Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $211.11, for a total value of $4,222,200.00. Following the sale, the director now directly owns 539,176 shares of the company’s stock, valued at $113,825,445.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Illumina, Inc. (ILMN) traded down 1.16% during mid-day trading on Thursday, hitting $210.96. The company had a trading volume of 508,379 shares. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $214.04. The firm has a market capitalization of $30.80 billion, a PE ratio of 42.33 and a beta of 0.81. The company’s 50 day moving average price is $196.85 and its 200-day moving average price is $180.11.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.14. The company had revenue of $662.00 million for the quarter, compared to analysts’ expectations of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The business’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.86 EPS. On average, analysts forecast that Illumina, Inc. will post $3.65 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was first reported by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/09/14/illumina-inc-ilmn-director-sells-4222200-00-in-stock.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. First Citizens Bank & Trust Co. lifted its position in Illumina by 0.4% in the 2nd quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences company’s stock valued at $536,000 after acquiring an additional 12 shares in the last quarter. Patten Group Inc. lifted its position in Illumina by 2.7% in the 1st quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after acquiring an additional 25 shares in the last quarter. Puzo Michael J lifted its position in Illumina by 0.4% in the 2nd quarter. Puzo Michael J now owns 5,955 shares of the life sciences company’s stock valued at $1,032,000 after acquiring an additional 25 shares in the last quarter. Flagship Harbor Advisors LLC lifted its position in Illumina by 1.7% in the 2nd quarter. Flagship Harbor Advisors LLC now owns 2,046 shares of the life sciences company’s stock valued at $345,000 after acquiring an additional 35 shares in the last quarter. Finally, Eqis Capital Management Inc. lifted its position in Illumina by 0.6% in the 2nd quarter. Eqis Capital Management Inc. now owns 6,914 shares of the life sciences company’s stock valued at $1,200,000 after acquiring an additional 38 shares in the last quarter. 93.34% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages recently commented on ILMN. Argus lifted their price objective on Illumina from $205.00 to $235.00 and gave the stock a “buy” rating in a research note on Wednesday. Leerink Swann reaffirmed an “outperform” rating and set a $225.00 price objective (up from $207.00) on shares of Illumina in a research note on Tuesday. Vetr cut Illumina from a “buy” rating to a “hold” rating and set a $209.78 price objective for the company. in a research note on Thursday, August 31st. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Finally, Barclays PLC reaffirmed an “equal weight” rating and set a $150.00 price objective on shares of Illumina in a research note on Wednesday, August 9th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $181.76.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.